Two legal frameworks, purpose-built for each sector A biotech founder is considering taking a proven human-health asset into animal health. The science translates and the market potential is real, but the regulatory pathway is different. Since January 2022, veterinary medicines…
The EU veterinary route for medtech & biotech founders Every few months, a MedTech founder hits the same wall: the technology is validated, but the human regulatory path is a multi-year climb before a single sale. Then someone raises the…
A practical guide for medtech and biotech founders Every few months, a founder faces the same fork: the science is sound, but revenue is years away. Then a board member asks the question that changes everything: « Have you thought about the…
How do you successfully take a British medtech product into France? On 10 July 2026, Strategic Healthcare Advisors (SHA) partnered with UK Business Centre Lille (UKBC) and the UK Department for Business, Innovation, Science and Trade (DBIST) to host a…
With 65% of Step 1 applications rejected for insufficient proof of ‘breakthrough innovation’, the EIC Accelerator’s Excellence criterion is a rigorous, evidence-based standard. Success hinges on three pillars: Evidence quality is key. Funded champions like Panntherapi and Mode Sensors succeed by presenting regulatory-grade proof and avoiding common…
With only 6–8% of applicants funded, the EIC Accelerator rewards strategic preparation, not chance. Success consistently comes down to three elements: complete teams that combine technical depth with regulatory and commercial expertise; credible market pull demonstrated through LOIs, pilots or strategic partnerships; and a clear European trajectory showing…
Reaching TRL 6 is now one of the most decisive factors in EIC Accelerator success — yet it remains one of the least understood. While the Work Programme requires applicants to enter at TRL 5, evaluators ultimately select companies that…
The 2026 EIC Accelerator introduces major changes that raise the bar for life sciences innovators, including €414 million for open calls, a doubled minimum equity investment of €1 million, and a mandatory TRL 5 threshold. These shifts prioritise later-stage companies…
On September 30th, founders, investors, and industry experts came together to explore a key question: How can French HealthTech startups successfully expand to the United States? The discussion led to the creation of a new guide, “French HealthTech Startups in…
Caroline Chauché, our Co-Managing Partner at Strategic Healthcare Advisors, recently hosted a roundtable with Scottish Development International to support epipole, a Scottish MedTech startup scaling into the French healthcare market. The session, titled “Cracking the Code: Entering the French Healthcare Market”, brought…
